Molecular Partners (MOLN) AI Stock Analysis

• Market Cap: $168.11M
• Dividend Yield: N/A
• Average Volume (3M): 2.31K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.93
• Revenue Growth: -100.00%
• EPS Growth: 11.02%
• Country: US
• Employees: 158
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.69
• Shares Outstanding: 40,374,640
• 10 Day Avg. Volume: 2,377
• 30 Day Avg. Volume: 2,311
• PEG Ratio: 0.17
• Price to Book (P/B): 1.04
• Price to Sales (P/S): 29.53
• P/FCF Ratio: -2.45
• Enterprise Value/Market Cap: 0.18
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -0.73
• Enterprise Value/Ebitda: -0.51
• 1Y Price Target: $10.00
• Price Target Upside: 137.53% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 42 Neutral
• Price Target: $4.00 ▼(-4.99% Downside)

The score is primarily weighed down by weak financial performance (near-zero TTM revenue, ongoing losses, and significant negative free cash flow) despite low leverage. Technicals are slightly negative in the near term with muted momentum, and valuation provides limited support because the company is loss-making and no dividend yield data is available.

Positive Factors

Proprietary DARPin platform

Molecular Partners’ proprietary DARPin platform is a structural competitive advantage: it enables multispecific, half-life engineered and radiolabeled constructs across oncology modalities. That platform-driven versatility supports durable program diversification and partner interest beyond single-drug risk.

Strategic partnerships and external expertise

Active collaborations (e.g., Orano Med) and engagement from consortia and KOLs materially de-risk development and commercialization pathways. Partnerships bring funding, radiopharma expertise, and distribution scale, improving the long-term chance that clinical assets reach patients and generate milestone/royalty revenues.

Multi-year cash runway

Management reports cash to fund operations into 2028, which provides a multi-year runway to advance multiple early-stage trials and nominate new candidates. A sustained runway reduces near-term financing pressure, allowing more controlled execution of pivotal data-generation and partnering strategies.

Negative Factors

Near-zero revenue and deep net losses

The company currently lacks recurring product revenue and records material net losses, meaning ongoing operations depend on milestone payments, external funding or equity raises. This structural absence of commercial cash flows increases dilution and operational risk until a partnered product reaches market.

Sustained negative cash flow

Consistent negative operating and free cash flow shows the business is consuming cash to fund trials rather than generating it. Unless clinical successes trigger milestones or partnerships, the structural cash burn limits internal capital for parallel programs and raises the likelihood of future financing at dilutive terms.

Eroding balance sheet equity and assets

Material declines in equity and total assets over recent periods reflect cumulative losses and balance-sheet consumption. This erosion reduces the company’s buffer against setbacks, weakens financial flexibility for large trials or commercial launches, and signals diminished shareholder value until positive cash flows emerge.

Molecular Partners Business Overview & Revenue Model

Company Description

Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, which is in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274 that is in Phase I clinical trials for HER2-positive cancers. It also develops MP0423 for treating COVID-19; MP0533, a CD3 T cell candidate for acute myeloid leukemia; and MP0250 for vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin to increase half-life. Molecular Partners AG has agreements and collaboration with Novartis AG to develop, manufacture, and commercialize DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and discovery alliance with AbbVie Inc. in ophthalmology, as well as other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

How the Company Makes Money

Molecular Partners generates revenue through a combination of strategic partnerships, research and development collaborations, and potential product sales. The company often enters into licensing agreements with larger pharmaceutical companies, providing them access to its DARPin technology in exchange for upfront payments, milestone payments tied to clinical and commercial achievements, and royalties on future sales. Additionally, the company may receive funding from grants or public investments aimed at supporting innovative biotech research. Key partnerships with major industry players can significantly enhance its financial resources and facilitate the development and commercialization of its products.

Molecular Partners Financial Statement Overview

Summary

Molecular Partners faces significant financial challenges, with declining revenue, negative profitability margins, and consistent net losses. While the balance sheet shows strong equity financing and low leverage, the company's cash flow and profitability issues raise concerns about its ability to sustain operations without external funding.

Income Statement

The company has experienced a decline in revenue over the past year, with a negative revenue growth rate of approximately -29.37% from 2023 to 2024. Gross profit margin is high at 100% in 2024 due to low total revenue, but net profit margin is negative due to substantial net losses, indicating challenges in controlling operational costs. EBIT and EBITDA margins are also negative, reflecting ongoing operational inefficiencies.

Balance Sheet

The balance sheet shows a relatively low debt-to-equity ratio of 0.02 in 2024, suggesting low leverage and financial risk. However, the equity ratio is high at 89.34%, indicating strong equity financing. Return on equity is negative due to net losses, which is a concern for profitability. Overall, the company has a solid equity base but struggles with profitability.

Cash Flow

The company reports negative free cash flow, which has slightly increased from the previous year's negative free cash flow. The operating cash flow to net income ratio is close to 1, indicating that cash flow performance aligns with net income losses. However, negative free cash flow is a concern for long-term sustainability.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	4.97M	7.04M	189.56M	9.33M	9.34M
Gross Profit	-40.40M	-42.53M	-40.81M	138.81M	-46.39M	-46.73M
EBITDA	-58.02M	-51.65M	-59.52M	119.00M	-60.66M	-59.58M
Net Income	-60.24M	-54.04M	-61.98M	117.85M	-63.78M	-62.76M
Balance Sheet
Total Assets	112.15M	158.53M	198.35M	262.26M	172.67M	187.55M
Cash, Cash Equivalents and Short-Term Investments	104.52M	149.44M	186.89M	249.14M	132.81M	173.72M
Total Debt	1.53M	2.44M	3.65M	4.85M	6.04M	7.22M
Total Liabilities	16.62M	16.89M	21.92M	27.09M	65.38M	80.33M
Stockholders Equity	95.53M	141.64M	176.43M	235.17M	107.29M	107.22M
Cash Flow
Free Cash Flow	-54.01M	-59.97M	-59.81M	117.15M	-92.26M	-30.67M
Operating Cash Flow	-53.30M	-59.25M	-59.01M	118.57M	-90.95M	-28.98M
Investing Cash Flow	56.10M	40.49M	44.64M	-101.12M	-22.24M	-21.75M
Financing Cash Flow	14.45M	14.43M	-1.17M	-1.57M	50.58M	113.20M

Molecular Partners Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 4.21
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MOLN, the sentiment is Positive. The current price of 4.21 is below the 20-day moving average (MA) of 4.28, below the 50-day MA of 4.25, and above the 200-day MA of 3.89, indicating a neutral trend. The MACD of -0.02 indicates Positive momentum. The RSI at 48.82 is Neutral, neither overbought nor oversold. The STOCH value of 19.71 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MOLN.

Molecular Partners Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
STTK	53 Neutral	$299.31M	-4.64	-57.84%	―	-84.46%	33.32%
CGEN	52 Neutral	$185.20M	-6.62	-52.95%	―	-88.47%	-1658.33%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
NKTX	48 Neutral	$147.03M	-1.49	-26.69%	―	―	25.84%
CCCC	44 Neutral	$225.81M	-1.39	-59.98%	―	-10.57%	1.98%
ONCY	43 Neutral	$112.99M	-3.74	-745.66%	―	―	―
MOLN	42 Neutral	$168.11M	-2.21	-49.86%	―	-100.00%	11.02%

Molecular Partners Corporate Events

Molecular Partners Launches New Clinical Trials and Maps 2026 Milestones Ahead of J.P. Morgan Healthcare Conference

On January 11, 2026, Molecular Partners reported broad clinical and pipeline progress ahead of its presentation at the 44th J.P. Morgan Healthcare Conference, underscoring its push to establish leadership in targeted radiotherapeutics and novel immune-oncology modalities. The company has initiated a Phase 1/2a U.S. trial of its lead Radio-DARPin MP0712 for small cell lung cancer and other neuroendocrine tumors, with first patient dosing expected in the first quarter of 2026 and initial data due later in the year, supported by encouraging compassionate-use imaging data to be shown at the Theranostics World Congress 2026. Its second radiotherapy program, MP0726 for mesothelin-positive cancers including ovarian cancer, continues to advance alongside four additional radio-oncology projects, guided by a new scientific advisory board of nuclear medicine experts. Beyond radiotherapy, a Phase 2 investigator-initiated trial of tumor-localized CD40 agonist MP0317 in cholangiocarcinoma has begun treating patients in early 2026, and the Phase 1/2a study of tetra-specific T cell engager MP0533 in relapsed/refractory AML is ongoing with densified dosing showing tolerability and early antitumor signals as of data presented in December 2025. Molecular Partners also plans to nominate its first Switch-DARPin candidate, a logic-gated T cell engager for solid tumors, in the first half of 2026. Financially, the company reported unaudited cash and cash equivalents of CHF 93.1 million as of December 31, 2025, which management believes will fund operations into 2028, providing a multi-year runway to execute its 2026 clinical and strategic milestones, with full 2025 results scheduled for March 12, 2026.

The most recent analyst rating on (MOLN) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Molecular Partners stock, see the MOLN Stock Forecast page.

Molecular Partners Presents Promising MP0533 Trial Data at ASH Meeting

On December 7, 2025, Molecular Partners presented updated data from their ongoing Phase 1/2a trial of MP0533, a multispecific T-cell engager, at the ASH Annual Meeting. The trial, which involves patients with relapsed/refractory acute myeloid leukemia (AML), demonstrated promising clinical benefits with an acceptable safety profile across various dosing regimens. The data indicated that MP0533 could significantly improve treatment options for AML patients, particularly those with low disease burden, and supports further investigation in a Phase 2 setting.

The most recent analyst rating on (MOLN) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Molecular Partners stock, see the MOLN Stock Forecast page.

Molecular Partners Unveils Promising MP0712 Data at TRP Summit

On November 12, 2025, Molecular Partners presented new data on its lead Radio-DARPin, MP0712, targeting DLL3 at the TRP Summit Europe. The data included initial human images showing specific uptake in primary tumors and metastatic lesions, supporting the mechanism of action. The company is preparing for a Phase 1 trial in the US by the end of 2025, with initial data expected in 2026. This development marks a significant milestone in the clinical advancement of MP0712, potentially impacting the treatment of small cell lung cancer and other neuroendocrine cancers.

The most recent analyst rating on (MOLN) stock is a Hold with a $4.50 price target. To see the full list of analyst forecasts on Molecular Partners stock, see the MOLN Stock Forecast page.

Molecular Partners Advances Clinical Pipeline with New IND Filing and Financial Update

On October 30, 2025, Molecular Partners announced its Q3 2025 financial results and clinical progress, highlighting the filing of an IND application for MP0712, a Radio-DARPin targeting DLL3, with a Phase 1 trial expected to start by the end of 2025. The company also shared updates on other programs, including MP0533 for AML and MP0317 for cholangiocarcinoma, alongside a strong financial position with a cash runway until 2028. These developments reflect Molecular Partners’ strategic advancements in oncology, potentially enhancing its industry standing and offering significant implications for stakeholders.

The most recent analyst rating on (MOLN) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Molecular Partners stock, see the MOLN Stock Forecast page.